Abstract
Rationale: The effectiveness of varenicline for smoking cessation has been established, but little is known about the psychological processes that mediate this clinical outcome. Objectives: This study evaluated the effect of a single dose of varenicline on tonic and cue-provoked changes in craving, withdrawal, and affect using a randomized, double-blind, placebo-controlled, cross-over design. Methods: Following overnight abstinence, 38 non-treatment-motivated smokers received either varenicline 2. mg or matched placebo, then tonic measures of craving, withdrawal, and positive and negative affect were obtained at 30-min intervals. At 4-h post-administration, a cue exposure session obtained the same subjective measures at three time-points following the physical handling of a lit cigarette versus the sharpening and handling of a pencil. Results: At 4-h post-administration, varenicline reduced tonic craving as well as craving across the smoking and neutral cue conditions, relative to placebo. By contrast, the capacity of the smoking cue to enhance craving relative to the neutral cue was unaffected by varenicline. Measures of withdrawal and positive and negative affect produced mixed results. Conclusions: Acute varenicline selectively attenuates tonic but not cue-provoked craving. This dissociation provides insight into the specific psychological processes that might mediate the effectiveness of varenicline, and highlights cue-provoked craving as a discrete target for advancing smoking cessation pharmacotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 135-141 |
Number of pages | 7 |
Journal | Drug and Alcohol Dependence |
Volume | 130 |
Issue number | 1-3 |
DOIs | |
State | Published - Jun 1 2013 |
Funding
This study was funded by Pfizer . The authors had full control of all primary data. Editorial support was provided by Michelle Jenvey, PhD and Abegale Templar, PhD of UBC Scientific Solutions and was funded by Pfizer Inc. Dr. Hitsman was supported by a Mentored Clinical Scientist Research Career Development Award ( K08 DA017145 ). Dr. Hogarth was supported by a UK MRC grant ( G0701456 ). Preliminary versions were presented at the 45th Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, FL, USA (4 December 2006) and 13th Annual Meeting of the Society for Research on Nicotine and Tobacco (24 February 2007).
Keywords
- Affect
- Craving
- Cue-reactivity
- Nicotine withdrawal
- Smoking cessation
- Varenicline
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)
- Toxicology
- Pharmacology